Načítá se...
Cell line access to revolutionize the biosimilars market
Biologic drugs are notoriously expensive. Biosimilars, though priced lower, are also costly. Analysis of the cost of production of biologics suggests that the cost of manufacture is in many cases less than 10% of the price in high-income countries, and less than a third of the price of biosimilars i...
Uloženo v:
| Vydáno v: | F1000Res |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
F1000 Research Limited
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6051195/ https://ncbi.nlm.nih.gov/pubmed/30057752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.14808.1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|